MAD in Cancer Patients: Safety of BMS-582664 in Patients With Advanced or Metastatic Solid Tumors

PHASE1CompletedINTERVENTIONAL
Enrollment

68

Participants

Timeline

Start Date

September 30, 2004

Primary Completion Date

October 31, 2007

Study Completion Date

September 30, 2008

Conditions
TumorsNeoplasm Metastasis
Interventions
DRUG

Brivanib

Tablets, Oral, 180 mg, once daily, until disease progression

DRUG

Brivanib

Tablets, Oral, 320 mg, once daily, until disease progression

DRUG

Brivanib

Tablets, Oral, 600 mg, once daily, until disease progression

DRUG

Brivanib

Tablets, Oral, 800 mg, once daily, until disease progression

DRUG

Brivanib

Tablets, Oral, 800 mg, once daily (5 days on, 2 days off), until disease progression

DRUG

Brivanab

Tablets, Oral, 1000 mg, once daily, until disease progression

Trial Locations (8)

20141

Local Institution, Milan

46202

Indiana University Med Center, Indianapolis

53792

University Of Wisconsin Comprehensive Center, Madison

90404

Premiere Oncology, Santa Monica

T6G 1Z2

Local Institution, Edmonton

K1H 1C4

Local Institution, Ottawa

HA6 2RN

Local Institution, Middlesex

M20 4BX

Local Institution, Manchester

Sponsors
All Listed Sponsors
lead

Bristol-Myers Squibb

INDUSTRY